| methylphenidate prolonged release tablet - 12 hrs acting / Generic mfg. |
NCT00866996: Community-based Study Comparing Extended-release Methylphenidate and Atomoxetine in Children With Attention-deficit Hyperactivity Disorder |
|
|
| Completed | 4 | 1323 | US | Methylphenidate extended-release; Atomoxetine | McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. | Attention Deficit Hyperactivity Disorder | | 12/03 | | |
NCT00302367: An Open Label Phase I/II Study of Dopamine Transporter Receptor Occupancy With OROS and Immediate Release Methylphenidate as Measured With C-11 Altropane in Human Subjects |
|
|
| Completed | 4 | 20 | US | OROS methylphenidate hydrochloride, immediate release methylphenidate hydrochloride | Massachusetts General Hospital, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. | Healthy Volunteers | 04/04 | 04/04 | | |
| Completed | 4 | 30 | US | atomoxetine (Strattera) | Massachusetts General Hospital, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. | ADHD NOS | | 07/05 | | |
NCT00181987: Concerta in the Treatment of ADHD in Youth and Adults With Bipolar Disorder |
|
|
| Completed | 4 | 29 | US | methylphenidate HCl (Concerta) | Massachusetts General Hospital, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. | ADHD, Bipolar Disorder | 08/05 | 08/05 | | |
NCT00302354: A Double-blind Randomized, Placebo-controlled, Crossover Study of Single Doses of OROS Methylphenidate Hydrochloride (CONCERTA) and Long-acting Methylphenidate Hydrochloride (RITALIN LA) in Healthy Adults |
|
|
| Completed | 4 | 50 | US | OROS methylphenidate HCl, SODAS methylphenidate HCl | Massachusetts General Hospital, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. | Healthy Volunteers | 09/05 | 09/05 | | |
NCT00318981: Efficacy of Concerta in Treating ADHD in Mothers of Children With ADHD |
|
|
| Completed | 4 | 40 | US | Concerta | University of Maryland, College Park, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Children's National Research Institute | Adult ADHD | | 12/06 | | |
NCT00302458: A Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults |
|
|
| Completed | 4 | 44 | US | OROS-Methylphenidate, Concerta, OROS MPH, Immediate Release Methylphenidate, IR MPH, Ritalin, Placebo | Massachusetts General Hospital, Ortho-McNeil Janssen Scientific Affairs, LLC | Healthy | 06/07 | 06/07 | | |
NCT00518232: A Study to Determine Effective and Tolerable Titration Scheme for OROS-Methylphenidate in Children With Attention-deficit Hyperactivity Disorder |
|
|
| Completed | 4 | 520 | RoW | OROS-methylphenidate | Johnson & Johnson Taiwan Ltd | Attention Deficit Hyperactivity Disorder | 06/07 | 06/07 | | |
NCT00181571: A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder |
|
|
| Completed | 4 | 297 | US | methylphenidate HCl (Concerta), Concerta, Placebo | Massachusetts General Hospital, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. | ADHD | 08/07 | 08/07 | | |
NCT00302406: Naturalistic Substitution of Concerta in Adult Subject With ADHD Receiving Immediate Release Methylphenidate |
|
|
| Completed | 4 | 50 | US | methylphenidate hydrochloride, OROS methylphenidate hydrochloride (CONCERTA) | Massachusetts General Hospital, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. | Attention Deficit Hyperactivity Disorder | 11/07 | 11/07 | | |
NCT00585910: Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD |
|
|
| Completed | 4 | 94 | US | Atomoxetine and OROS Methylphenidate, Strattera, Concerta | Massachusetts General Hospital, Ortho-McNeil Janssen Scientific Affairs, LLC | ADHD, Attention Deficit Hyperactivity Disorder | 12/07 | 12/07 | | |
CHOP, NCT00530257: Study of the Effects of Osmotic-Release Oral System (OROS) Methylphenidate (Concerta) on Attention and Memory |
|
|
| Completed | 4 | 30 | US | Placebo, OROS-methylphenidate, Concerta, Osmotic-Release Oral System -methylphenidate | Children's Hospital of Philadelphia, Ortho-McNeil Janssen Scientific Affairs, LLC | Attention Deficit Hyperactivity Disorder | 06/08 | 06/08 | | |
NCT00758160 / 2015-001216-35: The Impact of Osmotic Release Oral Delivery System Methylphenidate (OROS MPH) Upon Family of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD) |
|
|
| Completed | 4 | 296 | RoW | OROS Methylphenidate | Johnson & Johnson Taiwan Ltd, Johnson & Johnson Taiwan Ltd | Attention Deficit Disorder With Hyperactivity | 06/08 | 06/08 | | |
NCT00783835: Study to Evaluate the Efficacy and Quality of Life of Long-Acting Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD) |
|
|
| Completed | 4 | 60 | RoW | Long-Acting Methylphenidate, Concerta | Janssen-Cilag Farmaceutica Ltda. | Attention Deficit Hyperactivity Disorder | 10/08 | 10/08 | | |
NCT00799409: Lab School Day Study for CONCERTA of Older Children With ADHD |
|
|
| Completed | 4 | 78 | US | Placebo/ CONCERTA (methylphenidate HCl), CONCERTA (methylphenidate HCl) / Placebo | Ortho-McNeil Janssen Scientific Affairs, LLC | Attention Deficit Hyperactivity Disorder | 06/09 | 06/09 | | |
| Completed | 4 | 89 | US | CONCERTA (methylphenidate HCl) or placebo | Ortho-McNeil Janssen Scientific Affairs, LLC | Attention Deficit Hyperactivity Disorder | 06/09 | 06/09 | | |
NCT01012622: An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD) |
|
|
| Completed | 4 | 142 | RoW | Osmotic Release Oral System (OROS) Methylphenidate Hydrochloride | Janssen Korea, Ltd., Korea | Attention Deficit Disorder With Hyperactivity | 08/09 | 08/09 | | |
NCT00937040: Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD) |
|
|
| Completed | 4 | 357 | US | OROS MPH, Placebo, OROS MPH Tablets, Placebo Tablets | Ortho-McNeil Janssen Scientific Affairs, LLC | Attention Deficit Disorder With Hyperactivity | 02/10 | 02/10 | | |
NCT01060150 / 2015-001084-39: An Efficacy Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention-Deficit/Hyperactivity Disorder (ADHD) |
|
|
| Completed | 4 | 115 | RoW | OROS Methylphenidate HCl, Concerta | Janssen Korea, Ltd., Korea, Janssen Korea Ltd | Attention Deficit Disorder With Hyperactivity | 04/10 | 04/10 | | |
NCT00931398: Treatment of College Students With Attention-Deficit/Hyperactivity Disorder (ADHD) Using OROS Methylphenidate |
|
|
| Withdrawn | 4 | 0 | US | methylphenidate HCl (Concerta), Concerta, Placebo | University of Pittsburgh, Ortho-McNeil Janssen Scientific Affairs, LLC | Attention-Deficit/Hyperactivity Disorder (ADHD) | 04/10 | 04/10 | | |
NCT01933880: A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants |
|
|
| Completed | 4 | 194 | RoW | Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH), No intervention | Xian-Janssen Pharmaceutical Ltd. | Attention Deficit Hyperactivity Disorder (ADHD) | 11/10 | 11/10 | | |
NCT00778310: Neuroimaging of the Effects of Concerta in the Treatment of ADHD |
|
|
| Completed | 4 | 76 | US | methylphenidate-OROS, Placebo | The University of Texas Health Science Center at San Antonio, Ortho-McNeil Janssen Scientific Affairs, LLC | Attention Deficit Disorder With Hyperactivity | 12/10 | 12/10 | | |
NCT00181714: Prevention of Cigarette Smoking in Attention Deficit Hyperactivity Disorder (ADHD) Youth With Concerta |
|
|
| Completed | 4 | 203 | US | methylphenidate HCl (Concerta), Concerta | Massachusetts General Hospital, Ortho-McNeil Janssen Scientific Affairs, LLC | ADHD | 01/11 | 01/11 | | |
| Terminated | 4 | 23 | Europe | Atomoxetine, Strattera, LY139603, Osmotic-release oral system methylphenidate, Placebo | Eli Lilly and Company | Attention Deficit Hyperactivity Disorder | 05/11 | 05/11 | | |
NCT01063153: Diagnostic Utility of Attention Deficit Hyperactivity Disorder (ADHD) by Brain Activity Flow Patterns Analysis Using Evoked Response Potentials |
|
|
| Completed | 4 | 71 | US | Osmotic Release Methylphenidate, Concerta | Massachusetts General Hospital, ElMindA Ltd | Attention Deficit Hyperactivity Disorder | 02/12 | 02/12 | | |
NCT01552915: Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder |
|
|
| Completed | 4 | 464 | US | Lisdexamfetamine dimesylate, LDX, Vyvanse, SPD489, Methylphenidate Hydrochloride, OROS-MPH, Concerta, Placebo | Shire | Attention-deficit/Hyperactivity Disorder | 01/14 | 01/14 | | |
| Completed | 4 | 549 | Europe, Canada, US | Lisdexamfetamine dimesylate, SPD489, Vyvanse, LDX, Methylphenidate Hydrochloride, Concerta, OROS-MPH, Placebo | Shire | Attention-deficit/Hyperactivity Disorder | 05/14 | 05/14 | | |
2015-001081-26: Lab School Day Study for CONCERTA of Older Children with ADHD |
|
|
| | 4 | 78 | US | CONCERTA, Capsule, CONCERTA | Ortho-McNeil Janssen Scientific Affairs LLC, Ortho-McNeil Janssen Scientific Affairs | Attention Deficit Hyperactivity Disorder, being hyperactive and/or inattentive, Diseases [C] - Nervous System Diseases [C10] | | | | |
2015-001084-39: An Efficacy Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention-Deficit/Hyperactivity Disorder (ADHD) |
|
|
| | 4 | 125 | RoW | CONCERTA, Capsule, CONCERTA | Janssen Korea Ltd, Janssen Korea Ltd | Attention Deficit Hyperactivity Disorder, being hyperactive and/or inattentive, Diseases [C] - Nervous System Diseases [C10] | | | | |
2015-001217-27: An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD) |
|
|
| | 4 | 142 | RoW | CONCERTA, Capsule, CONCERTA | Janssen Korea Ltd, Janssen Korea Ltd | Attention Deficit Hyperactivity Disorder, being hyperactive and/or inattentive, Diseases [C] - Nervous System Diseases [C10] | | | | |
2015-001218-92: A study to evaulate the most favourable treatment dose in childrens and adolescents with Attention-Deficit Hyperactivity Disorder |
|
|
| | 4 | 145 | RoW | CONCERTA, Capsule, CONCERTA | Janssen Korea Ltd, Janssen Korea Ltd | Attention Deficit Hyperactivity Disorder, being hyperactive and/or inattentive, Diseases [C] - Nervous System Diseases [C10] | | | | |
2015-001070-18: A study to determine effective and tolerable titration scheme for OROS-Methylphenidate in Children with Attention-deficit hyperactivity disorder |
|
|
| | 4 | 520 | RoW | CONCERTA, Prolonged-release capsule, CONCERTA | Janssen-Cilag Taiwan, Janssen-Cilag Taiwan | Attention Deficit Hyperactivity Disorder, being hyperactive and/or inattentive, Diseases [C] - Nervous System Diseases [C10] | | | | |
2014-002002-20: A multicentre randomized double-blind placebo controlled discontinuation trial of methylphenidate |
|
|
| Ongoing | 4 | 120 | Europe | Capsule, hard, Concerta | UMCG, ZonMw, Shire | attention-deficit/hyperactivity disorder, attention-deficit/hyperacitivity disorder (ADHD), Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04] | | | | |
| Unknown status | 4 | 1344 | Europe, US, RoW | Short Acting Methylphenidate, • Ritalin, • Ritalina, • Attenta, • Methylin, • Penid, • Rubifen, *Consider treatment directions above or as physician directed as per usual care., Long Acting Methylphenidate, • Concerta, • Metadate CD, • Methylin ER, • Ritalin LA, • Ritalin Sustained-Release | BRC Operations Pty. Ltd. | Attention Deficit/Hyperactivity Disorder | 12/19 | 12/19 | | |
RE-DAX, NCT04507204: Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) |
|
|
| Terminated | 4 | 267 | US | Adhansia XR, Methylphenidate hydrochloride (HCl) extended release, Concerta, Methylphenidate hydrochloride (HCl) | Purdue Pharma LP | Attention-Deficit/Hyperactivity Disorder | 12/21 | 01/22 | | |
